Clinical Trial Update: Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome [Phase 3]

View source ↗

Summary

Phase 3 open-label extension trial of intravenous mepolizumab for hypereosinophilic syndrome was terminated, with results posted in December 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypereosinophilic Syndrome

Drugs mentioned

• Mepolizumab (mepolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hypereosinophilic Syndrome | Phase 3 | Status: TERMINATED | Results posted: 2015-12-15